Stock market technical analysis forecast | Nasdaq trend research for trading investing | 401k
trading penny stock breakout day investing
Skip Navigation Links
    Home
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event
    Login


Join Now




Advertise 2 ۩  Daily market forecast

Hot Penny Stock picks for investing - support resistance research

BBI Blockbuster Inc (BBI)
Sector 
RecommendationsBuy
Buy Near0.76
Stop Loss0.70
Posted Date1/18/2010 12:00:00 AM
First resistance0.92
Second resistance1.03
Third resistance1.38
First Support0.60
Second Support0.62
Comments
1/18/2010 12:00:00 AM0) Blockbuster Inc (BBI) is a leading global provider of rental and retail movies and games
1) This penny Stock company (BBI) provides customers with convenient access to media entertainment anywhere, any way they want it - whether in-store, by-mail, through vending kiosks or digitally downloaded directly to their family room or mobile device
2) Blockbuster Inc (BBI) have library of more than 125,000 movies and games
3) Blockbuster Inc (BBI) recently announced that it has eliminated the final $24 million of certain letters of credit it maintained on behalf of its former parent company, Viacom Inc and this stapes naturally increase the liquidity of cash, again Blockbuster Inc (BBI) raised $675 million on our bond offering to extend our debt maturities into 2014

As per technical analysis of this penny Stock ADX and Stockhastic given a buy signal and it Started up trend with RSI positive divergence and recently it breakout with very high volume
4) Recent company’s action also supporting our positive view, so Blockbuster Inc (BBI) you can consider for breakout penny Stock portfolio, and you can enter near $0.76 with $0.60 stop loss
5) This Stock trading with high volume so you can consider for penny Stock day trading also
6)

DM crossover and raising ADX with Stockhastic buy signal and breakout with high volume and sustain breakout point on following day is a ideal condition to buy Stock and in this penny Stock you found all this factors, still keep stop loss because penny Stock when turn negative we never know, so protect your investment stop loss is important
7)
BBI
Brickell Biotech to Participate in September Virtual Investor Conferences
(Thu, 10 Sep 2020 20:05:00 +0000)
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the 4th Annual Lake Street Best Ideas Growth Conference and the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit, both being held in September 2020.Details are as follows:Conference: 4th Annual Lake Street Best Ideas Growth Conference (virtual) Date: Thursday, September 17, 2020 1v1 investor meetings onlyConference: Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit (virtual) Date: Monday, September 21, 2020 Time: 4:10 PM ET Webcast: Link Fireside chat & 1v1 investor meetingsA live webcast of the fireside chat at the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit will also be available in the investors section of the Brickell Biotech website at https://ir.brickellbio.com/events-presentations. After the live webcast, the event will remain archived on the Brickell Biotech website for approximately 90 days.About Brickell Bio Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.
(Tue, 08 Sep 2020 11:30:00 +0000)
Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in JapanIBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, through which Brickell has the right to develop AnGes’ proprietary investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets. AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, with data readouts expected through the first quarter of 2021. The results from these studies will guide AnGes’ and Brickell’s global development efforts of this novel vaccine candidate. “We are pleased to enter into this collaboration agreement with Brickell in which we intend to leverage know-how, data and capabilities that Brickell acquired through its merger last year with another vaccine company,” said Ei Yamada, President and Chief Executive Officer of AnGes. “This collaboration also provides the opportunity to expand our vaccine candidate into additional markets outside of Japan.”Under the terms of this agreement, AnGes will continue to lead the development of its vaccine candidate in Japan and Brickell will provide information and know-how that could be relevant to such development efforts. In exchange for this, Brickell has received the right to develop and, if approved, commercialize AnGes’ DNA vaccine in the U.S. and certain underserved countries.“We are excited by the opportunity to work with AnGes, a leading vaccine developer in Japan, to potentially bring a COVID-19 vaccine to the U.S. and other countries to help address the global pandemic. AnGes is at the forefront of developing a vaccine for COVID-19 and was the first company in Japan to initiate a COVID-19 vaccine clinical study,” commented Robert Brown, Chief Executive Officer of Brickell. “While Brickell remains firmly focused on initiating its U.S. Phase 3 pivotal program for sofpironium bromide for the treatment of primary axillary hyperhidrosis later this year, we look forward to reviewing AnGes’ clinical study results and then working together with them and the FDA to determine the best path forward.”About AnGesAnGes, Inc. is a biopharmaceutical company founded in December 1999 based on an innovative discovery by researchers at Osaka University and focuses on the development of gene-based medicine. For our lead product, HGF Plasmid (gene therapy) for the treatment of critical limb ischemia, the company got the conditional and time-limited approval in March 2019. And its commercialization started in September 2019 in Japan. This is the world’s first commercialization using the Plasmid DNA method. Development of NF-κB Decoy Oligonucleotide for diseases including low back pain, and DNA vaccines for high blood pressure is also under way. Furthermore, AnGes started co-development of the DNA vaccine with Osaka University from March 2020 for COVID-19 in Japan. The DNA vaccine for COVID-19 utilizes the method of Plasmid DNA. For more information, visit https://www.anges.co.jp/en/About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s lead product candidate is sofpironium bromide, a novel and potential best-in-class treatment for primary axillary hyperhidrosis. The Company expects to initiate its U.S. Phase 3 pivotal program for sofpironium bromide in the fourth quarter of 2020. In addition, Brickell’s Japanese development partner for sofpironium bromide, Kaken Pharmaceutical Co., Ltd., expects to receive a regulatory decision for sofpironium bromide gel, 5% in Japan, later this year.Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, legal, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing or future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Brickell, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes unsuccessful clinical studies, unanticipated demands on cash resources, any disruption to our business caused by the current COVID-19 pandemic, interruptions, delays or negative determinations on Kaken’s new drug application under current review, or on AnGes’ development efforts for its lead COVID-19 vaccine candidate, including the outcome of ongoing and planned clinical trials in regard to this asset, and other risks associated with developing and obtaining regulatory approval for and commercializing product candidates.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at http://www.sec.gov (or at http://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.AnGes Investor Contact: Public Relations & Investor Relations Group TEL: +81-3-5730-2641 FAX: +81-3-5730-2635Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office
(Mon, 31 Aug 2020 20:05:00 +0000)
Claims directed to novel crystalline forms of sofpironium bromidePatent protection in Japan granted through 2040BOULDER, Colo., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that Brickell and its Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”), were granted by the Japanese Patent Office a composition of matter patent with claims directed to the novel polymorphic, or crystalline, forms of sofpironium bromide, a retrometabolically designed new chemical entity, currently under development in the United States and Japan as a potential best-in-class treatment for primary axillary hyperhidrosis. This patent is expected to provide additional protection in Japan through 2040 for these newly developed and distinct characterized crystalline forms of sofpironium bromide. Patent protection for these crystalline forms of sofpironium bromide currently is being pursued worldwide, including in the United States.“The issuance of this new composition of matter patent is a key accomplishment in protecting and expanding upon our intellectual property portfolio,” commented Robert Brown, Chief Executive Officer of Brickell. “We are pleased by this important new patent issuance in Japan, as well as the continued progress Kaken is making in their commercial planning for sofpironium bromide in Japan. Kaken expects to receive a regulatory decision for sofpironium bromide gel, 5% in Japan, later this year.”About Sofpironium BromideSofpironium bromide is a proprietary new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. This proposed mechanism of action may allow for highly effective doses to be used while limiting systemic side effects. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. Sofpironium bromide is not approved for use in any country at this time.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and more than 16 million people, or 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States or 10 million individuals and an estimated 45% of patients with hyperhidrosis in Japan or 7.2 million individuals1,2. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, legal, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Brickell, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, unanticipated demands on cash resources, any disruption to our business caused by the current COVID-19 pandemic, interruptions, delays or negative determinations on Kaken’s new drug application under current review, and other risks associated with developing and obtaining regulatory approval for and commercializing novel therapeutics.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at http://www.sec.gov (or at http://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.1 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.com
Brickell Biotech Reports Second Quarter 2020 Financial Results and Provides Corporate Update
(Wed, 12 Aug 2020 20:01:00 +0000)
Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide gel as early as the fourth quarter of 2020 Brickell plans to initiate its U.S. pivotal Phase 3 program in the fourth quarter of 2020BOULDER, Colo., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.“We announced several milestones during the first half of 2020 that strengthened our ability to execute our strategy to develop sofpironium bromide as a treatment for primary axillary hyperhidrosis in the U.S. and in Japan. Most notable are the successful completion of our U.S. Phase 3 long-term safety study, the positive Phase 3 pivotal study results in Japan for sofpironium bromide presented in June by our Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”), and an equity financing for net proceeds of $18.7 million,” commented Robert Brown, Chief Executive Officer of Brickell. “These important achievements position us well to move towards the anticipated initiation of our U.S. Phase 3 pivotal program in the fourth quarter of 2020. We continue to be excited by the prospects of sofpironium bromide as a potential best-in-class treatment for primary axillary hyperhidrosis and look forward to keeping our shareholders updated on our R&D progress.”Business and Recent Developments * In July 2020, Brickell completed the analysis of its 12-month Phase 3 open-label long-term safety study, in 300 subjects 9 years and older with primary axillary hyperhidrosis, sofpironium bromide gel, 5% and 15%. The study results confirmed that sofpironium bromide gel, at both concentrations, was safe and generally well tolerated, which was consistent with the earlier Phase 2 clinical trial results. No treatment-related serious adverse events were observed. Brickell expects to release additional details at an upcoming scientific forum.   * In June 2020, Brickell announced positive Phase 3 pivotal study results in Japan from Kaken. All primary and secondary efficacy endpoints of the study were achieved and sofpironium bromide was safe and generally well tolerated. The study evaluated a total of 281 Japanese patients randomized 1:1 to apply sofpironium bromide gel, 5% (SB) or vehicle gel (placebo) to the axillae (i.e., underarm) for 42 days. These study results were presented as part of the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Virtual Meeting Experience. * In January 2020, Kaken announced submission of a new drug application in Japan requesting approval to manufacture and market sofpironium bromide gel, 5% for primary axillary hyperhidrosis based on the positive Phase 3 data. * In June 2020, Brickell completed an equity offering resulting in net proceeds of approximately $18.7 million. The Company anticipates using the proceeds from the offering for research and development, including clinical trials, working capital, and general corporate purposes.Upcoming Milestones * Plan to initiate the U.S. Phase 3 pivotal program for sofpironium bromide gel, 15% in the fourth quarter of 2020.  The planned program will be comprised of two pivotal Phase 3 trials to evaluate approximately 350 subjects per trial with primary axillary hyperhidrosis in the U.S.  The first Phase 3 study is expected to begin in the fourth quarter of 2020. * Expect Kaken to receive regulatory decision for sofpironium bromide gel, 5% in Japan, as early as the fourth quarter of 2020. Under the agreement with Kaken, Brickell is entitled to receive commercial milestone payments, as well as tiered royalties based on a percentage of net sales of sofpironium bromide in Japan.Financial ResultsThe Company reported cash and cash equivalents and marketable securities of $21.6 million as of June 30, 2020 compared to $11.7 million as of December 31, 2019. In addition, Brickell has prepaid $4.6 million to third-party clinical research organizations in anticipation of commencing Phase 3 pivotal clinical trials of sofpironium bromide in the U.S. later this year.Revenue was $0.6 million for the second quarter of 2020 compared to $2.6 million for the second quarter of 2019. Revenue in both periods was driven by research and development activities related to the agreement with Kaken pursuant to which Kaken provided research and development funding to Brickell. The decrease in revenue recognized was attributable to Brickell’s Phase 3 long-term safety study of sofpironium bromide gel and other ancillary clinical studies that were ongoing in 2019 but were concluded or winding down by the end of the first quarter of 2020. Conducting these studies is the basis for revenue recognition for a $15.6 million research and development payment received from Kaken in the second quarter of 2018.Research and development expenses were $2.7 million for the second quarter of 2020 compared to $4.2 million for the second quarter of 2019. This decrease was primarily due to reduced clinical and other related regulatory and administrative costs of the Phase 3 long-term safety study of sofpironium bromide gel and other ancillary clinical studies that were concluded or winding down by the end of the first quarter of 2020. Expenses in the second quarter of 2020 included $1.5 million in paid or accrued milestone payments to the licensor of sofpironium bromide. Research and development expenses are expected to increase following the initiation of the Phase 3 program for sofpironium bromide.General and administrative expenses were $3.0 million for the second quarter of 2020 compared to $1.3 million for the second quarter of 2019. This increase was primarily due to higher costs of $0.9 million for professional-related fees related to capital-raising activities and additional expenses incurred for operating as a public company, $0.6 million for stock and other compensation expense, and $0.3 million for directors’ and officers’ liability insurance fees due to becoming a public company.Total other income, net was $7.0 thousand for the second quarter of 2020 compared to total other expense, net of $0.7 million for the second quarter of 2019. The change was primarily due to a decrease of $0.7 million in interest expense related to the issuance of convertible promissory notes in 2019 and principal borrowings provided by a loan agreement with a former lender.Brickell’s net loss was $5.1 million for the second quarter of 2020 compared to $3.7 million for the second quarter of 2019.Conference Call and Webcast InformationBrickell’s management will host a conference call today at 4:30 p.m. ET to discuss the financial results and recent corporate developments. The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID 13706625. A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at http://www.brickellbio.com. A replay will be available on this website shortly after conclusion of the event for 90 days.About Sofpironium BromideSofpironium bromide is a proprietary new molecular entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. This proposed mechanism of action may allow for highly effective doses to be used while limiting systemic side effects. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. Sofpironium bromide is not approved for use in any country at this time.About HyperhidrosisHyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and more than 16 million people, or 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States or 10 million individuals and an estimated 45% of patients with hyperhidrosis in Japan or 7.2 million individuals1,2. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.About BrickellBrickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.Cautionary Note Regarding Forward-Looking StatementsAny statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of future clinical trials, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Brickell, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development (including the U.S. Phase 3 pivotal program for sofpironium bromide), potential delays for any reason in product development, regulatory changes, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, delays or negative determinations on Kaken’s new drug application under review, and other risks associated with developing, and obtaining regulatory approval for and commercializing novel therapeutics.Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at http://www.sec.gov (or at http://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.                                 1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749. 2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.Brickell Investor Contact: Dan Ferry LifeSci Advisors (617) 430-7576 daniel@lifesciadvisors.comBrickell Biotech, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30,  2020 2019 2020 2019 Collaboration revenue$607   $2,573   $1,653   $6,065            Operating expenses:        Research and development2,712   4,229   5,376   10,248   General and administrative3,021   1,323   5,502   3,389   Total operating expenses5,733   5,552   10,878   13,637   Loss from operations(5,126)  (2,979)  (9,225)  (7,572)  Investment and other income, net7   4   3   10   Interest expense—   (660)  —   (884)  Change in fair value of derivative liability—   (11)  —   (11)  Change in fair value of warrant liability—   (8)  —   223   Net loss(5,119)  (3,654)  (9,222)  (8,234)  Reduction (accretion) of redeemable convertible preferred stock to redemption value—   (163)  —   10,356   Net income (loss) attributable to common stockholders$(5,119)  $(3,817)  $(9,222)  $2,122   Net income (loss) per common share attributable to common stockholders, basic$(0.43)  $(6.48)  $(0.87)  $3.60   Net loss per common share attributable to common stockholders, diluted$(0.43)  $(6.48)  $(0.87)  $(4.46)  Weighted-average shares used to compute net income (loss) per share attributable to common stockholders, basic11,819,152   589,001   10,595,960   589,001   Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted11,819,152   589,001   10,595,960   1,845,467   Brickell Biotech, Inc. Selected Financial Information Condensed Consolidated Balance Sheet Data (amounts in thousands) (unaudited)      June 30, 2020 December 31, 2019 Cash and cash equivalents$21,570  $7,232  Marketable securities, available-for-sale—  4,497  Prepaid expenses and other current assets5,736  6,240  Total assets27,430  18,144  Total liabilities7,520  10,570  Total stockholders’ equity19,910  7,574
Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
(Mon, 03 Aug 2020 20:05:00 +0000)
BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Wednesday, August 12, 2020. Brickell’s management will host a conference call and webcast at 4:30pm ET to discuss the financial results and recent corporate highlights.To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13706625. To access the live webcast, please go to the investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.About Brickell Bio Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.Brickell Investor Contact: IR@brickellbio.com
HCKT Hackett Group, Inc
SectorServices
RecommendationsBuy
Buy Near2.12
Stop Loss1.88
Posted Date6/6/2009 1:32:46 AM
First resistance3.04
Second resistance3.38
Third resistance5.44
First Support2.00
Second Support1.88
Comments
6/6/2009 3:45:25 PM0) Penny Stock Alert - Hackett Group, Inc
1) (HCKT) is a global strategic advisory firm and company is a leader in best practice advisory, benchmarking, and transformation consulting services, including shared services, outsourcing and off shoring advice
2) Hackett business application consulting services helps costumer to maximize returns on IT investments At the end of the first quarter of 2009, the Hackett Group, Inc
3) (HCKT) got cash balance $26.3 million, and as per company Stock repurchase plan, the Company already repurchased approximately 1.0 million shares at average price $2.08 per share, for a total cost of $2.1 million
4) And still approximately $4.8 million remained available under the Company’s share repurchase program.

Based on the current economic Outlook, the Hackett Group, Inc
5) (HCKT) estimates total revenue for the second quarter of 2009 to be in the range of $34.0 M to $36.0 M and estimates earnings per share to be in the range of $0.00 to $0.03. Recently Wipro Technologies (WIT) announced they partnered with Oracle for best-of-breed HR platform solutions and for that Wipro has also selected The Hackett Group (HCKT), to provide empirical data, best practices and world-class Performance insights on the development of its innovative bundled solution platform
6) The solution, allows employers to reduce and control cost as it provides an opportunity to centralize and standardize processes while eliminating duplicative management structures
7)

As per chart analysis Hackett Group, Inc
8) (HCKT) Relative Strength (RSI) started to strengthening, rate of change also got good moment again there are strong demand closer to $2.12 that indicating accumulation going on, with good capital in hand and suitable to present economy business model offering over all best penny Stock investing option
9)
HCKT
The Hackett Group, Inc. (NASDAQ:HCKT) Pays A US$0.095 Dividend In Just Four Days
(Sat, 19 Sep 2020 12:33:43 +0000)
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
Is Hackett Group (HCKT) Stock a Suitable Value Pick Now?
(Mon, 14 Sep 2020 13:30:01 +0000)
Let's see if The Hackett Group, Inc. (HCKT) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
If You Had Bought Hackett Group's (NASDAQ:HCKT) Shares A Year Ago You Would Be Down 21%
(Mon, 24 Aug 2020 16:03:20 +0000)
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
NVEE vs. HCKT: Which Stock Is the Better Value Option?
(Fri, 07 Aug 2020 15:40:03 +0000)
NVEE vs. HCKT: Which Stock Is the Better Value Option?
Did Hedge Funds Make The Right Call On The Hackett Group, Inc. (HCKT)?
(Wed, 05 Aug 2020 22:23:56 +0000)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
LOJN LO-JACK CORP COM
SectorSecurity Systems & Services
RecommendationsBuy
Buy Near3.84
Stop Loss3.21
Posted Date2/8/2009 12:00:00 AM
First resistance5.33
Second resistance6.73
Third resistance7.20
First Support3.41
Second Support3.21
Comments
2/8/2009 12:42:24 PM0) LoJack Corporation (LOJN), the company that invented the stolen vehicle recovery market more than two decades ago, is the global leader in finding and recovering a wide range of mobile assets including cars, construction equipment and motorcycles having recovered more than $5 billion USD in stolen assets worldwide
1) In today's rapidly changing world, LoJacks core competencies are more valuable and more relevant than ever as they are now being applied into new areas, such as the prevention, detection and recovery of stolen cargo and finding and rescuing people with cognitive disorders such as Alzheimers and autism
2) LoJack has the proven processes, ultimate technology for recovery ,Radio Frequency and unique integration with law enforcement agencies, making its offerings the most effective solutions that not only deliver a wide range of recoveries, but also enhance the safety of the public on a global level
3) LoJacks Stolen Vehicle Recovery System operates in 26 states and the District of Columbia, and in more than 30 countries throughout North America, South America, Europe, Africa and Asia
4) This Penny Stock looks good candidate for portfolio investment
5) Before to invest Penny Stock understand your risk
6) To manage your risk keep tight stop loss on all investment.
LOJN
ANAD ANADIGICS Inc
SectorSemiconductors
RecommendationsBuy
Buy Near2.16
Stop Loss1.90
Posted Date2/8/2009 12:00:00 AM
First resistance2.55
Second resistance3.06
Third resistance3.92
First Support2.16
Second Support1.90
Comments
2/8/2009 12:45:38 PM0) ANADIGICS, Inc
1) is a provider of semiconductor solutions in the broadband wireless and wire line communications markets
2) The Company’s products include power amplifiers (PAs), tuner integrated circuits, active splitters, line amplifiers and other components, which can be sold individually or packaged as integrated radio frequency (RF) and front end modules This penny Stock closer to its strong support and looks good candidate for portfolio investment
3) Before to invest in penny Stock understand the risk factor
4) Due to market and economic condition keep tight stop loss on all investment.
ANAD
CHUX O CHARLEYS INC COM
SectorRestaurants
RecommendationsBuy
Buy Near2.66
Stop Loss1.96
Posted Date2/8/2009 12:00:00 AM
First resistance3.14
Second resistance5.44
Third resistance7.30
First Support2.05
Second Support1.23
Comments
2/8/2009 12:50:26 PM0) OCharleys Inc
1) is a casual dining restaurant company
2) The Company owns and operates three restaurant concepts under the OCharleys, Ninety Nine and Stony River Legendary Steaks trade names
3) As of December 30, 2007, it operated 229 OCharleys company owned restaurants in 16 states in the Southeast and Midwest, 115 Ninety Nine restaurants in nine Northeastern states, and ten Stony River restaurants in six states in the Southeast and Midwest OCharleys beats by $0.13, misses on revs Reports Q4 (Dec) loss of $0.15 per share, $0.13 better than the First Call consensus of ($0.28); revenues fell 5.7% year/year to $202.9 mln vs the $206.8 mln consensus The main difference here is that OCharleys would have still closed out its latest quarter in the red without writing down the value of its assets
4) This penny Stock closer to its strong support and looks good candidate for portfolio investment
5) Before to invest in any penny Stock understand your risk
6)
CHUX
ACTG Acacia Research Corporation
SectorTechnology : Electronic Instr. & Controls
RecommendationsBuy
Buy Near3.01
Stop Loss2.42
Posted Date1/1/2009 12:00:00 AM
First resistance3.61
Second resistance4.60
Third resistance5.55
First Support3.01
Second Support2.84
Comments
1/1/2009 8:55:19 PM0) Acacia Research Corporation (ACTG) has given a breakout with high volume and also given a buy signal, with rising moving average
1) Stockhastic, rate of change (ROC) and ADX also given a buy signal Acacia Research Corporation (ACTG) announced on Dec 31 2008 that its subsidiary, Data Network Storage LLC, Telematics Corporation, International Printer Corporation and Light Valve Solutions LLC has entered into a settlement and license agreement with the Hewlett-Packard Company relates to storage area networks, Datatrac Corporation, Océ, N.V
2) and Océ North America, Inc
3) and Hitachi, Ltd respectively
4) Recently Acacia Research Corporation (ACTG) bought the rights to a patent related to wireless data technology and its subsidiary, Acacia Patent Acquisition LLC, has acquired the rights to patents relating to vehicle occupant sensing technology.

As per technical analysis and fundamental research Acacia Research Corporation (ACTG) looks good candidate for penny Stock investing as well as you can add in portfolio investment
5) Recently ACTG given a breakout with rising moving average and also Stockhastic and Rate of change (ROC) given a buy signal
6) Acacia Research Corporation (ACTG) you can consider for Investment, Swing Trading, penny Stock Investing, Day trading
7) Due to market and economic condition keep tight stop loss on all position
8) You can buy Acacia Research Corporation (ACTG) near $3.01
ACTG
Trade Alert: Maureen O'Connell At Acacia Research Corporation (NASDAQ:ACTG), Has Just Spent US$94k Buying 22% More Shares
(Thu, 10 Sep 2020 10:03:21 +0000)
Whilst it may not be a huge deal, we thought it was good to see that Maureen O'Connell, who is a company insider...
Acacia Research's(NASDAQ:ACTG) Share Price Is Down 59% Over The Past Five Years.
(Tue, 01 Sep 2020 10:34:28 +0000)
While not a mind-blowing move, it is good to see that the Acacia Research Corporation (NASDAQ:ACTG) share price has...
Acacia Research Reports Second Quarter 2020 Financial Results
(Mon, 10 Aug 2020 12:00:00 +0000)
Acacia Research Corporation ("we," "us," "our," "Acacia" or "the Company") (Nasdaq: ACTG) today reported results for the three-month period ended June 30, 2020.
Acacia Research to Release Second Quarter Financial Results
(Wed, 29 Jul 2020 20:30:00 +0000)
Acacia Research Corporation ("Acacia" or "the Company") (NASDAQ: ACTG) announced today it will release its second quarter financial results on Monday, August 10, 2020 at 8:00 a.m. ET/ 5:00 a.m. PT.
Were Hedge Funds Right About Being Bullish On Acacia Research Corporation (ACTG)?
(Fri, 03 Jul 2020 22:27:22 +0000)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
LAB LABRANCHE & CO INC COM
SectorFinancial
RecommendationsBuy
Buy Near6.23
Stop Loss4.72
Posted Date11/2/2008 12:00:00 AM
First resistance7.43
Second resistance7.98
Third resistance11.80
First Support5.70
Second Support4.72
Comments
11/3/2008 12:00:04 AM0) LaBranche & Co Inc.com (LAB)Stocks given a double top breakout on 10/31/08 with good volume again many technical indicators also have given a buy signal, with rising moving average
1) Stockhastic and ADX also given a buy signal
2) LaBranche & Co Inc.com (LAB) is a Stock-exchange specialist firm
3) As per technical analysis and fundamentally LaBranche & Co Inc.com (LAB) look good candidate for portfolio investment. LaBranche & Co Inc.com you can consider for Investment, Swing trading, Stock trading, penny Stock Investing, Day trading
4) Due to market and economic condition keep tight stop loss on all position
5) You can buy LaBranche & Co Inc.com (LAB) near $6.23
LAB


Next Page >>   

 

























Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006 Flyingstock.com
Penny Stock picks for Stock trading Penny Stock investing support resistance

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.